Descripción del proyecto
Una bomba implantable inteligente para la insuficiencia cardíaca avanzada
La insuficiencia cardíaca es un trastorno potencialmente mortal en el que el corazón es incapaz de bombear suficiente sangre para satisfacer las necesidades del cuerpo. Para los enfermos con una insuficiencia cardíaca avanzada y que son demasiado mayores o no adecuados para un trasplante cardíaco, los dispositivos de asistencia ventricular izquierda (DAVI, o LVAD por sus siglas en inglés) implantables han surgido como una nueva opción de tratamiento. El proyecto financiado con fondos europeos Calypso comercializará un DAVI revolucionario desarrollado por la empresa francesa CORWAVE. Este dispositivo nuevo está basado en una tecnología de vanguardia patentada: la membrana de onda. A diferencia de los dispositivos actuales, que son bombas rotatorias de flujo continuo, CorWave LVAD es una bomba inteligente que produce un flujo sanguíneo fisiológico y pulsátil para devolver una vida normal a los enfermos con unos efectos secundarios mínimos.
Objetivo
Advanced heart failure (HF) is a deadly disease, with a booming incidence driven by durable socio-demographic trends. Left ventricular assist devices (LVADs) are a life-saving therapy for advanced HF patients and represent a billion-euro market. However, only 13% of the 60,000 eligible patients are implanted with current LVADs each year, due to the extremely high rate of severe adverse events (stroke, bleeding, infection) and the limited quality of life.
CorWave is an innovative French SME created in 2011 with a mission to create a new standard of care for advanced HF patients. The company is developing a game-changing LVAD, which relies on a unique and patented breakthrough technology, the wave membrane. Unlike all current devices, which are continuous-flow rotary pumps, CorWave LVAD is a smart pump producing a physiologic and pulsatile blood flow, to restore a normal life to patients with minimal side effects. CorWave LVAD will cut in half severe complications and rehospitalisation costs. CorWave projects to take over 60% of the market and reach up to €1.1 billion of turnover in 2030, by taking advantage of the LVAD market structure, which is very favourable to new entrants (concentrated on a few centres), and by increasing the penetration rate.
We have built a team of 50 experienced people, including world-class experts, and have gained a strong market traction. The clinical centres who support us through letters of intent are worth >25% of the European market. We partner with a network of industrial suppliers and have our own pilot production unit to manufacture prototypes that have proved successful in preclinical studies.
Thanks to EIC Accelerator, CorWave will transform a very promising preclinical prototype (TRL 6-7) into an industrial CE-marked medical device (TRL 8-9) that patients, clinicians and payers are waiting for. EIC Accelerator would place CorWave on a trajectory to become a global medtech leader with an outstanding socioeconomic impact on the EU.
Ámbito científico
Not validated
Not validated
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-EIC-SMEInst-2018-2020-3
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
92110 Clichy
Francia
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.